New Year’s Contemplation by MVIC CEO

MVIC CEO, Lars Asking, gives his summarised view on year 2023 at MVIC.

2023 was another good year for MVIC. We have had, and are having, a range of customers in various fields of inhaled drug delivery including formulation development, measurement undertakings and nonclinical activities. Furthermore, MVIC member companies are without exception doing well. We are a commercial CRO but many activities are scientific and we have several links to academia. We are excited to move into 2024 – please contact us and share your challenges in inhaled drug delivery. I am sure we can help!

Lars Asking, CEO of MVIC

Share on LinkedIn

Related news articles